Pirlimycin

Pirlimycin is an orally active lincosamide Antibiotic, Clindamycin (HY-B1455) analog, and antimalarial agent. Pirlimycin inhibits Plasmodium growth. Pirlimycin exhibits antibacterial activity against various aerobic bacteria, particularly Staphylococcus and Streptococcus species. Pirlimycin can be used for research on bovine mastitis^{[1][2][3][4][5][6][7]}. In Vitro:Pirlimycin (0.5-4.0 μg/mL; 20-24 h) exhibits high overall in vitro activity against Streptococcus agalactiae isolates from bovine mastitis (83.7% susceptible, overall MIC₅₀ = 0.5 μg/mL; MIC₉₀ >4 μg/mL)^[3].
Pirlimycin (0.5-4.0 μg/mL; 20-24 h) is susceptible to both Cluster Ia and Cluster II Streptococcus agalactiae isolates (MIC₅₀ and MIC₉₀ = 0.5 μg/mL), whereas Cluster Ib isolates show significantly reduced susceptibility^[3].
Pirlimycin exhibits in vitro antibacterial activity against a variety of aerobic bacteria, particularly Staphylococcus and Streptococcus species, with MIC values ranging from ≤0.012 to >25 μg/mL^[4]. In Vivo:Pirlimycin (s.c. or p.o.; daily; 4 days) exhibits superior in vivo antibacterial and antiplasmodial efficacy compared to Clindamycin (HY-B1455) in mice, with CD₅₀ values ranging from 0.25 to 20.3 mg/kg depending on the organism and route of administration^[4].
Pirlimycin (intramammary injection; 1 h post-infection) combined with rhTNF-α significantly reduces intramammary S. aureus bacterial counts, exhibiting an additive effect compared with either agent alone in a mouse model of staphylococcal mastitis^[6].